The University of North Dakota (UND) and Neomatrix, LLC, announced today that they have signed an exclusive agreement to develop technology for the early detection of breast cancer using the company’s HALO® Breast Pap Test device.
The HALO® breast test is for physicians and is designed to help screen and assess breast cancer risk in women using techniques from cell biology. The UND technology, used with the HALO® device, is based on the detection of cancer indicators in breast nipple aspirate fluid (NAF).
Early detection of breast cancer is widely recognized as the most effective strategy for successfully treating the disease. Health outcomes are greatly improved when breast cancer is discovered in the early stages of development.
To learn more about this exciting development click here.